Table Graph
      published meta-analysis   sensitivity analysis   studies

Spikevax (Moderna mRNA-1273 COVID-19 vaccine) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias confirmed Covid-19, from 1st dosedetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 0.05 [0.03; 0.09] 0.05[0.03; 0.09]COVE Moderna/NIH phase 3 (study 301), 202010%28,207NAnot evaluable death D28detailed resultsHusby (Moderna), 2021 0.41 [0.37; 0.46] 0.41[0.37; 0.46]Husby (Moderna), 202110%NAnot evaluable deathsdetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 0.50 [0.02; 14.84] 0.50[0.02; 14.84]COVE Moderna/NIH phase 3 (study 301), 202010%28,207NAnot evaluable vaccine efficacy from randomization (ITT)detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 0.07 [0.04; 0.11] 0.07[0.04; 0.11]COVE Moderna/NIH phase 3 (study 301), 202010%29,148NAnot evaluable confirmed COVID (any severity)detailed resultsButt, 2021 0.02 [0.01; 0.02] Southern California (Tseng) - delta, 2022 0.05 [0.04; 0.06] Southern California (Tseng) - omicron, 2022 0.70 [0.51; 0.95] 0.08[0.01; 0.71]Butt, 2021, Southern California (Tseng) - delta, 2022, Southern California (Tseng) - omicron, 2022399%115,377lownot evaluable hospitalizationdetailed resultsMayo Clinic (Puranik), 2021 0.19 [0.04; 0.81] 0.19[0.04; 0.81]Mayo Clinic (Puranik), 202110%45,828NAnot evaluable symptomatic Covid-19detailed resultsAndrejko, 2021 0.14 [0.06; 0.31] Canada (Nasreen), 2021 0.08 [0.04; 0.15] Chung, 2021 0.06 [0.03; 0.13] COVE Moderna/NIH phase 3 (study 301), 2020 0.06 [0.03; 0.11] Mayo Clinic (Puranik), 2021 0.24 [0.13; 0.43] Nanduri, 2021 0.49 [0.44; 0.55] Qatar (Tang), 2021 0.15 [0.10; 0.24] 0.14[0.06; 0.30]Andrejko, 2021, Canada (Nasreen), 2021, Chung, 2021, COVE Moderna/NIH phase 3 (study 301), 2020, Mayo Clinic (Puranik), 2021, Nanduri, 2021, Qatar (Tang), 2021795%380,371moderateserious severe COVID-19 occurrencedetailed resultsCanada (Nasreen), 2021 0.06 [0.03; 0.11] COVE Moderna/NIH phase 3 (study 301), 2020 0.02 [0.00; 0.27] Grannis, 2021 0.05 [0.03; 0.08] Mayo Clinic (Puranik), 2021 0.19 [0.04; 0.81] Qatar (Tang), 2021 0.07 [0.00; 1.37] 0.06[0.04; 0.08]Canada (Nasreen), 2021, COVE Moderna/NIH phase 3 (study 301), 2020, Grannis, 2021, Mayo Clinic (Puranik), 2021, Qatar (Tang), 202150%84,076seriousnot evaluable serious adverse eventsdetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.04 [0.78; 1.40] 1.04[0.78; 1.40]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable adverse eventsdetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.14 [1.08; 1.20] 1.14[1.08; 1.20]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable convulsions/seizures detailed resultsKlein, 2021 1.04 [0.84; 1.29] 1.04[0.84; 1.29]Klein, 202110%150NAnot evaluable disseminated intravascular coagulation detailed resultsKlein, 2021 0.70 [0.39; 1.27] 0.70[0.39; 1.27]Klein, 202110%25NAnot evaluable Guillain-Barré syndrome detailed resultsKlein, 2021 0.70 [0.22; 2.27] 0.70[0.22; 2.27]Klein, 202110%6NAnot evaluable immune thrombocytopenia detailed resultsKlein, 2021 1.12 [0.64; 1.95] 1.12[0.64; 1.95]Klein, 202110%23NAnot evaluable ischemic strokedetailed resultsKlein, 2021 0.97 [0.87; 1.08] 0.97[0.87; 1.08]Klein, 202110%650NAnot evaluable Myocardial infarction detailed resultsKlein, 2021 1.02 [0.89; 1.17] 1.02[0.89; 1.17]Klein, 202110%375NAnot evaluable myocarditisdetailed resultsHusby (Moderna), 2021 3.92 [2.30; 6.68] Klein, 2021 1.18 [0.78; 1.78] 2.12[0.65; 6.89]Husby (Moderna), 2021, Klein, 2021292%39moderatenot evaluable pericarditis detailed resultsKlein, 2021 1.18 [0.78; 1.78] 1.18[0.78; 1.78]Klein, 202110%39NAnot evaluable pulmonary embolismdetailed resultsKlein, 2021 1.01 [0.86; 1.19] 1.01[0.86; 1.19]Klein, 202110%290NAnot evaluable Transverse myelitis detailed resultsKlein, 2021 1.45 [0.07; 31.68] 1.45[0.07; 31.68]Klein, 202110%1NAnot evaluable venous thromboembolism detailed resultsKlein, 2021 1.16 [1.00; 1.34] 1.16[1.00; 1.34]Klein, 202110%327NAnot evaluable VTE with thrombocytopeniadetailed resultsKlein, 2021 0.86 [0.58; 1.27] 0.86[0.58; 1.27]Klein, 202110%53NAnot evaluable cerebral venous sinus thrombosis (CVST)detailed resultsKlein, 2021 1.55 [0.33; 7.28] McMurry, 2021 0.50 [0.02; 14.82] 1.27[0.31; 5.21]Klein, 2021, McMurry, 202120%686,456seriousnot evaluable appendicitisdetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 0.67 [0.11; 3.99] Klein, 2021 0.82 [0.73; 0.93] 0.82[0.73; 0.92]COVE Moderna/NIH phase 3 (study 301), 2020, Klein, 202120%30,842criticalnot evaluable arthralgia, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 18.37 [13.54; 24.91] 18.37[13.54; 24.91]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable Bell's palsydetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 3.00 [0.31; 28.83] Klein, 2021 1.00 [0.86; 1.17] Li X, 2022 0.99 [0.57; 1.73] McMurry, 2021 0.20 [0.03; 1.33] 0.98[0.73; 1.32]COVE Moderna/NIH phase 3 (study 301), 2020, Klein, 2021, Li X, 2022, McMurry, 2021418%30,652seriousnot evaluable hypersensitivity, all termsdetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.41 [1.15; 1.72] 1.41[1.15; 1.72]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable lymphadenopathy, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97] 1.00[0.06; 15.97]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable musculoskeletal and connective tissue disorders, anydetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97] 1.00[0.06; 15.97]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable myalgia, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 27.64 [20.93; 36.50] 27.64[20.93; 36.50]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable fever, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 43.29 [17.83; 105.10] 43.29[17.83; 105.10]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable local adverse reaction, any, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 33.74 [31.59; 36.03] 33.74[31.59; 36.03]COVE Moderna/NIH phase 3 (study 301), 202010%29,235NAnot evaluable local adverse reaction, grade 3-4, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 15.04 [11.83; 19.12] 15.04[11.83; 19.12]COVE Moderna/NIH phase 3 (study 301), 202010%29,235NAnot evaluable systemic adverse reaction, any, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 6.69 [6.35; 7.05] 6.69[6.35; 7.05]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable systemic adverse reaction, grade 3-4, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 9.50 [8.38; 10.77] 9.50[8.38; 10.77]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable0.0100.01.0relative treatment effectwww.metaEvidence.org2024-06-01 03:01 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 755 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons